-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Anemia is a common complication of chronic kidney disease (CKD) patients, erythropoietin agent (of ESAs) CKD patients with anemia is most commonly used treatment, can normalize to 13.
0-14.
0 g / dL hemoglobin level of the patient, but will result in a patient heart blood vessels events , venous thrombosis embolism and increased risk of death
.
Daprodustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHIs), which triggers the body to adapt to hypoxia and promotes bone marrow to produce more red blood cells, thereby reducing anemia
Heart vascular events thrombosis recently researchers studied in patients with CKD not receiving dialysis in comparison with traditional ESAs, Daprodustat efficacy and safety
In this randomized, public, phase III trial, researchers compared the efficacy of Daprodustat and alfadabetine in the treatment of anemia in CKD patients who did not undergo dialysis
.
The primary endpoint of the study was the average change in the patient’s hemoglobin level from baseline examination to weeks 28-52, and the first major adverse cardiovascular event (MACE; death from any cause, non-fatal myocardial infarction, or non-fatal stroke)
Myocardial infarction
3872 patients participated in the study, and baseline hemoglobin levels were similar between groups
.
From baseline check to week 28-52, the average change in hemoglobin level in the Daprodustat group was 0.
The average change in hemoglobin level in the Daprodustat group was 0.
Changes in hemoglobin levels between groups
Changes in hemoglobin levels between groups Changes in hemoglobin levels between groupsStudies believe that in patients with CKD anemia who have not received dialysis, Daprodustat treatment is equivalent to the erythropoiesis agent alfadarbetine in improving hemoglobin levels and cardiovascular safety
In patients with CKD anemia who have not undergone dialysis, Daprodustat treatment is equivalent to the erythropoiesis agent alfadabetine in improving hemoglobin levels and cardiovascular safety.
Original source: Original source:
Ajay K.
Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis.
Leave a message here
